您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > CP-547632
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
CP-547632
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CP-547632图片
CAS NO:252003-65-9
包装:10mg, 50mg
包装与价格:
包装价格(元)
10mg电议
50mg电议

产品介绍

生物活性

CP-547632是一种新型的、有效的血管内皮生长因子受体-2酪氨酸激酶抑制剂,用于癌症治疗。血管内皮生长因子(VEGF)受体信号通路是内皮细胞增殖和迁移的关键途径,从而导致血管生成,这是人类肿瘤生长和转移的必要条件。CP-547632被鉴定为VEGFR-2和碱性成纤维细胞生长因子(FGF)激酶的有效抑制剂(IC(50)分别为11和9 nM)。与表皮生长因子受体、血小板衍生生长因子β和其他相关的tk相比,它具有选择性。在全细胞实验中,CP-547632也抑制vegf刺激的VEGFR-2的自磷酸化,IC(50)值为6 nM。在NIH3T3/H-ras肿瘤小鼠口服CP-547632后,肿瘤中的VEGFR-2磷酸化受到剂量依赖性的抑制(EC(50) = 590 ng/ml)。CP-547632对紫杉醇和卡铂的药理学特征没有显著影响。在体内,CP-547632可有效抑制碱性FGF和vegf诱导的血管生成。CP-547632是一种耐受性良好的口服生物可利用抑制剂,目前正在临床研究用于人类恶性肿瘤的治疗。


化学数据

分子量532.4
分子式C20H24BrF2N5O3S
CAS号252003-65-9
纯度>98%
溶解性(25°C)DMSO
储存和运输条件固体粉末: -20°C 冷藏长期储存
常温运输及临时存放

实验操作 来自于公开的文献,仅供相同实验参考(如实验材料、目的不同,请参考其他文献)

细胞实验
细胞系Porcine aortic endothelial cells
方法Cells were seeded at 1.6 × 105cells/ml in 2-ml growth medium (Ham’s F-12 medium supplemented with 10% FBS, 50,000 units each penicillin and streptomycin, and 500 μg/ml gentamicin) per well in six-well plates. On day 2, the growth medium was replaced with serum-depleted medium (as above, but with 0.1% FBS and 0.1% BSA), and cells were incubated overnight. Immediately before compound addition, the medium was replaced with serum-depleted medium without BSA. Compounds were diluted in 100% DMSO, added to the cells at a final DMSO concentration of 0.25% v/v, and incubated at 37°C for 1 h. The cells were then stimulated with 500 ng/ml VEGF (Becton Dickinson, prepared in serum-depleted medium supplemented with 10 mm NaVO4) and incubated as above for an additional 8 min. The medium was removed and the cells washed once with PBS supplemented with 1 mm NaVO4, then lysed with 1 ml of immunoprecipitation assay buffer [10 mm Tris-HCl (pH 7.5), 50 mm NaCl, 25 mm EDTA, 1% NP40, 0.25% sodium deoxycholate, 2 mm NaVO4, and 1 EDTA-free complete protease inhibitor tablet per 25 ml]. Cell lysates were centrifuged at 14,000 rpm to pellet cellular debris, transferred to a new tube containing 4 μg anti-Flk-1 (Santa Cruz Biotechnology Laboratories; C20), and incubated with agitation overnight at 4°C. The antibody-protein complex was captured with protein A agarose beads (Santa Cruz Biotechnology Laboratories) for 30 min at 4°C and the protein boiled off in the presence of DTT. After electrophoresis and transfer to Immobilon-P membranes, the blots were probed with antibodies recognizing either the protein (monoclonal anti-Flk-1; Santa Cruz Biotechnology Laboratories; A3) or anti-PY-HRP. After incubation of the blot in enhanced chemiluminescence reagent (Amersham), bands were visualized on film or using the Lumi-ImagerF1 (Roche).
浓度0~10 μ M
处理时间1 h

动物实验
动物模型athymic mice bearing Colo-205, DLD-1; and MDA-MB-231 cells tumour xenograft
配制5% Gelucire
剂量6.25–100 mg/kg qd. for 24 days
给药处理oral gavage

不同实验动物依据体表面积的等效剂量转换表(数据来源于FDA指南)

小鼠大鼠豚鼠仓鼠
重量 (kg)0.020.151.80.40.0810
体表面积 (m2)0.0070.0250.150.050.020.5
Km系数36128520
动物 A (mg/kg) = 动物 B (mg/kg) × 动物 B的Km系数
动物 A的Km系数

例如,依据体表面积折算法,将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量,需要将20 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到化合物用于大鼠的等效剂量为10 mg/kg。


储备液配制

以下数据基于产品分子量,对于特殊产品,请参照COA中的储备液配制条件和说明进行操作。

Concentration / Solvent Volume / Mass1 mg5 mg10 mg
1 mM1.8783 mL9.3914 mL18.7829 mL
5 mM0.3757 mL1.8783 mL3.7566 mL
10 mM0.1878 mL0.9391 mL1.8783 mL